A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)

Study Overview
=================
Brief Summary
-----------------
This is a randomized, 2-part, 2-arm, open-label, parallel-group, multi-center study to compare the PK of etrolizumab administered subcutaneously by an AI (test device) or a PFS-NSD (reference device) in healthy participants. The study will comprise a pilot cohort (Part 1) to estimate the geometric mean ratio (GMR) and variability of the maximum observed concentration (Cmax) and area under the concentration-time curve (AUC) to confirm or determine the sample size for the pivotal cohort (Part 2). The pivotal cohort will demonstrate exposure comparability of Cmax, AUC from Hour 0 to the last measurable concentration (AUClast), and AUC from Hour 0 to extrapolated infinite time (AUC0-inf), values for a single dose of etrolizumab administered subcutaneously either by the AI or the PFS-NSD.

Official Title
-----------------
A Randomized, Open-Label, 2-Part, 2-Arm, Parallel-Group, Single-Dose, Multi-Center Study in Healthy Subjects to Investigate the Comparability of Pharmacokinetics of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device or an Auto-Injector

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Drug: Etrolizumab
* Device: Auto-Injector (AI)
* Device: Prefilled Syringe With Needle Safety Device (PFS-NSD)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Within the body weight range of 60 to 100 kilograms, inclusive (for the pivotal cohort [Part 2] only) Within body mass index (BMI) range 18.0 to 30.0 kilograms per square meter (kg/m^2), inclusive In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), and vital signs Females will be non-pregnant, non-lactating, and either postmenopausal (at least 12 months of non-therapy-induced amenorrhea)/surgically sterile (e.g., tubal ligation, hysterectomy) for at least 90 days prior to enrolment, or agree to remain abstinent/use a highly effective method of contraception for at least 24 weeks after study drug administration Males will either be sterile or agree to remain abstinent/use a highly effective method of contraception for at least 24 weeks after study drug administration. Male participants will refrain from sperm donation from Check-in (Day -1) until 24 weeks following study drug administration Exclusion Criteria: Any prior treatment with etrolizumab or other anti-integrin agents (including natalizumab, vedolizumab, and efalizumab) Any prior treatment with anti-mucosal addressin cell adhesion molecule 1 (anti-MAdCAM-1) agents Any prior treatment with rituximab Received intravenous corticosteroids within 30 days prior to Screening Use of agents that deplete B or T cells (e.g., alemtuzumab, rituximab, or visilizumab) within 12 months prior to randomization Any prior immunosuppressive agents (including cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil) Chronic nonsteroidal anti-inflammatory drug (NSAID) use Use of any prescription medications/products within 14 days prior to Check in (Day -1) History of demyelinating disease Neurological conditions or diseases History of cancer History of alcoholism or drug addiction within less than (<) 1 year prior to Screening History of active or latent tuberculosis (TB), regardless of treatment history History of recurrent opportunistic infections and/or history of severe disseminated viral infections Positive for human immunodeficiency virus (HIV) antibody Any current or recent signs or symptoms of infection Pregnant or lactating Hospitalized within 4 weeks prior to and during Screening History of organ transplant Presence of skin rash at Screening or history of other skin disorders Tattoos, scars, chronic rashes, or sunburn in the area of the designated injection site

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Part 1: Etrolizumab AI<br>Participants will receive a single dose of etrolizumab via subcutaneous (SC) injection using the AI on Day 1. | Drug: Etrolizumab<br>* Etrolizumab will be administered at a dose of 105 milligrams (mg).<br>* Other names: RO5490261;Device: Auto-Injector (AI)<br>* The pre-filled AI will be used to administer etrolizumab.<br>|
| Active Comparator: Part 1: Etrolizumab PFS-NSD<br>Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1. | Drug: Etrolizumab<br>* Etrolizumab will be administered at a dose of 105 milligrams (mg).<br>* Other names: RO5490261;Device: Prefilled Syringe With Needle Safety Device (PFS-NSD)<br>* The PFS-NSD will be used to administer etrolizumab.<br>|
| Experimental: Part 2: Etrolizumab AI<br>Participants will receive a single dose of etrolizumab via SC injection using the AI on Day 1. | Drug: Etrolizumab<br>* Etrolizumab will be administered at a dose of 105 milligrams (mg).<br>* Other names: RO5490261;Device: Auto-Injector (AI)<br>* The pre-filled AI will be used to administer etrolizumab.<br>|
| Active Comparator: Part 2: Etrolizumab PFS-NSD<br>Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1. | Drug: Etrolizumab<br>* Etrolizumab will be administered at a dose of 105 milligrams (mg).<br>* Other names: RO5490261;Device: Prefilled Syringe With Needle Safety Device (PFS-NSD)<br>* The PFS-NSD will be used to administer etrolizumab.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Part 1: Cmax of Etrolizumab |  | Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71) | 
| Part 1: AUClast of Etrolizumab |  | Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71) | 
| Part 1: AUC0-inf of Etrolizumab |  | Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71) | 
| Part 1: Ratio of AUClast to AUC0-inf (AUCR) of Etrolizumab |  | Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71) | 
| Part 2: Cmax of Etrolizumab |  | Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71) | 
| Part 2: AUClast of Etrolizumab |  | Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71) | 
| Part 2: AUC0-inf of Etrolizumab |  | Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Part 1: Time to Maximum Observed Concentration (tmax) of Etrolizumab |  | Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71) | 
| Part 2: tmax of Etrolizumab |  | Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71) | 
| Part 1: Apparent Terminal Elimination Half-Life (t1/2) of Etrolizumab |  | Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71) | 
| Part 2: t1/2 of Etrolizumab |  | Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71) | 
| Part 2: AUCR of Etrolizumab |  | Predose (0 hours) and 6 hours postdose on Day 1, on Days 2, 4, 6, 8, 11, 15, 29, 43, 57, and at end of study (Day 71) or early discontinuation (up to Day 71) | 
| Percentage of Participants With Adverse Events |  | Part 1 and 2: Baseline up to Day 71 | 
| Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Etrolizumab |  | Part 1 and 2: Baseline up to Day 71 |